CLAIMS

1. ~~A method of~~ Use of semaglutide in the manufacture of a medicament for the treatment of non-alcoholic steatohepatitis (NASH) ~~comprising administration of semaglutide to a subject~~.

2. The ~~method~~ use according claim 1, wherein ~~said~~ a subject being treated further has liver fibrosis stage 1-3 according to the Kleiner fibrosis classification.

3. The ~~method~~ use according to claim 1, wherein ~~said~~ a subject being treated further has liver fibrosis stage 2 or 3 according to the Kleiner fibrosis classification.

4. The ~~method~~ use according to any one of the preceding claims, wherein said ~~method~~ treatment is for chronic management of NASH.

5. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is the sole active ingredient or the sole GLP-1 receptor agonist to be administered to said subject.

6. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered by subcutaneous administration.

7. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount in the range of about 0.7 to about 5 mg per week.

8. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount in the range of about 2.0 to about 3.5 mg per week.

9. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount in of about 2.4 mg per week.

10. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount in of about 2.8 mg per week.

11. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered once daily or less frequent.

12. The ~~method~~ use according to claim 11, wherein said semaglutide is to be administered once weekly.

13. The ~~method~~ use according to any one of the preceding claims, wherein said ~~method~~ treatment provides no worsening of liver fibrosis in said subject.

14. The ~~method~~ use according to any one of the preceding claims, wherein said semaglutide is to be administered in the form of a pharmaceutical composition in the form of an aqueous solution comprising one or more pharmaceutically acceptable excipients.

15. The ~~method~~ use according to claim 14, wherein said pharmaceutical composition is an aqueous solution comprising about 1.0 mg/ml semaglutide, about 1.42 mg/ml disodium hydrogen phosphate dihydrate, about 14.0 mg/ml propylene glycol, about 5.50 mg/ml phenol at about pH 7.4.

16. Use of semaglutide in the manufacture of a medicament for the treatment of non-alcoholic steatohepatitis (NASH), wherein said semaglutide is to be administered to a subject by subcutaneous administration in an amount of about 2.4 mg once weekly.

17. Use of semaglutide in the manufacture of a medicament for the treatment of non-alcoholic steatohepatitis (NASH), wherein said semaglutide is to be administered to a subject by once daily oral administration in the form of a solid composition, such as a tablet, comprising about 5-45 mg semaglutide and SNAC, such as at least 30% (w/w) SNAC.